Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Suarez-Almazor

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Trials|March 29, 2018
Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study ProtocolAyano Kelly, Allison Tong, Kathleen Tymms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Trials|March 29, 2018
Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study ProtocolAyano Kelly, Allison Tong, Kathleen Tymms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
Pageof 5